FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2292-2294 May 27, 2004 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Thompson, I. M. PubMed Citation

Prostate cancer is the second leading cause of death from cancer among men in the United States. In the era before prostate-specific antigen (PSA) screening, most prostate cancers were identified at a stage (T2 or T3) that could not be cured. Today, with the widespread use of PSA screening, most prostate cancers are identified at an earlier stage, which can be treated effectively with surgical or nonsurgical approaches. Once PSA screening became widespread in the United States, the rate of death from prostate cancer declined — for example, in 1997 it fell below the rate recorded in 1986, a year . . . [Full Text of this Article]

Source Information

From the Department of Urology, Johns Hopkins School of Medicine, Baltimore.

This article has been cited by other articles:

• Lucia, M. S., Darke, A. K., Goodman, P. J., La Rosa, F. G., Parnes, H. L., Ford, L. G., Coltman, C. A. Jr., Thompson, I. M. (2008). Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention. Cancer Prevention Research 1: 167-173 [Abstract] [Full Text]  
• Xiao, Z., Halls, S., Dickey, D., Tulip, J., Moore, R. B. (2007). Fractionated versus Standard Continuous Light Delivery in Interstitial Photodynamic Therapy of Dunning Prostate Carcinomas. Clin. Cancer Res. 13: 7496-7505 [Abstract] [Full Text]  
• Carter, H. B., Ferrucci, L., Kettermann, A., Landis, P., Wright, E. J., Epstein, J. I., Trock, B. J., Metter, E. J. (2006). Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.. JNCI J Natl Cancer Inst 98: 1521-1527 [Abstract] [Full Text]  
• Lee, S. E., Byun, S.-S., Park, H. K., Shim, H. B., Ku, J. H. (2006). Detection of Prostate Cancer at Low and Intermediate Serum Prostate-Specific Antigen Levels in a Country with a Low Incidence of Prostate Cancer. Jpn J Clin Oncol 36: 376-380 [Abstract] [Full Text]  
• Saraiya, M., Kottiri, B. J., Leadbetter, S., Blackman, D., Thompson, T., McKenna, M. T., Stallings, F. L. (2005). Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002. Cancer Epidemiol. Biomarkers Prev. 14: 2178-2182 [Abstract] [Full Text]  
• Welch, H. G., Schwartz, L. M., Woloshin, S. (2005). Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal. JNCI J Natl Cancer Inst 97: 1132-1137 [Abstract] [Full Text]  
• Malik, G., Ward, M. D., Gupta, S. K., Trosset, M. W., Grizzle, W. E., Adam, B.-L., Diaz, J. I., Semmes, O. J. (2005). Serum Levels of an Isoform of Apolipoprotein A-II as a Potential Marker for Prostate Cancer. Clin. Cancer Res. 11: 1073-1085 [Abstract] [Full Text]  
• (2004). Prostate Cancer Among Men with PSA ≤4.0 ng/mL. JWatch General 2004: 3-3 [Full Text]